FDA Grants Bexmarilimab Orphan Drug Designation for MDS
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with myelodysplastic syndromes.
Read More
Rusfertide Shows Superior Efficacy in Phase 3 Polycythemia Vera Trial
Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY study.
First Patient Dosed in Study of Iadademstat Combo in MDS
The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.
Fedratinib Shows Safety, Potential as Post-Transplant Therapy in MPNs
Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
Yang Highlights Positive COMMANDS Trial Data for Luspatercept in MDS
During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.
Reevaluating Available Options for Anemia in Myelofibrosis
During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for myelofibrosis in the second of 2 articles.
